Matinas BioPharma said pre-market Monday that a phase 1 trial of its oral version of the antibiotic amikacin yielded blood levels well below the safety limits for IV-administered amikacin at all tested doses.Shares were up 10% in recent pre-market. The drug was well-tolerated with no serious adverse events observed, the company said. IV-administered amikacin is used to treat chronic and acute bacterial infections.
Following its phase 1 meeting with the U.S. Food and Drug Administration the company plans to launch a phase 2 study in patients with NTM lung disease. The company will also evaluate opportunities to conduct human drug interaction studies and studies in special patient populations, such as patients with cystic fibrosis or non-lung Mycobacterum abscessus infections.